Loading clinical trials...
Loading clinical trials...
Bariatric Surgery and Pharmacokinetics of Valsartan: BAR-MEDS Valsartan
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on valsartan are investigated.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
St. Olavs University Hospital
Trondheim, Norway
Start Date
November 2, 2016
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
June 6, 2025
12
ESTIMATED participants
Valsartan
DRUG
Lead Sponsor
Norwegian University of Science and Technology
Collaborators
NCT03868592
NCT05242835
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05918575